undamentalytics Newsletter
Sign in

Mirum Pharmaceuticals, Inc. (MIRM) stock

Add to watchlist

Add holding +

NASDAQ: MIRM Nasdaq Biotechnology Next results ~November 3, 2026

C Fundamentals grade

Mirum Pharmaceuticals, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

Under review: free cash flow after stock pay is not positive.

Price vs value

Under review: free cash flow after stock pay is not positive. We'll show the comparison once resolved.

Mirum Pharmaceuticals, Inc. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders1 buying, 7 selling1 purchase and 59 sales by directors and officers, last 12 monthsInsider trades
  • Funds185 adding, 141 cuttingOf 63 active managers that changed their stake, 29 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Mirum Pharmaceuticals files

Where Mirum Pharmaceuticals stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $618m, up 44.0% on a year earlier, slower than the 50.2% growth a quarter earlier. Free-cash-flow margin fell to -37.0% from 2.0% a year earlier. Operating margin narrowed to -134.9% from -13.3%. The diluted share count is up 15.3% on a year earlier, which dilutes existing holders. Against its peers on growth, profitability, cash generation and balance sheet, it grades D. It passes 1 of our 5 financial-health checks.

Our model value for Mirum Pharmaceuticals is under review, so past values are not shown until it is resolved.

Source: 10-Q filed August 5, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 3, 2026 (estimated)

Mirum Pharmaceuticals, Inc.'s trailing-twelve-month revenue grew 44.0% year on year, with a free-cash-flow margin of -37.0%. Where it lags: long-term debt as % of assets of 71.8% ranks 74 of 78 biotechnology companies we cover.

Current signal Revenue growth decelerating: TTM revenue growth slowed to 44.0% (-6.2pp vs the prior quarter), the 2nd consecutive quarterly slowdown.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Fast growth. Revenue grew 44.0% over the last 12 months, against a median of 12.6% for biotechnology companies we cover.

Things to watch

  • Growth slowing. The growth rate is 6.2 points lower than a quarter earlier.
  • Loss-making. Operating margin is -134.9%: costs exceed revenue.
  • Margins narrowing. Operating margin is down 121.6 points on a year ago.
  • Burning cash. Free cash flow was -37.0% of revenue over the last 12 months.
  • Heavy stock-based pay. Stock pay equals 16.8% of revenue, against a median of 19.2% for biotechnology companies we cover: a real cost that cash-flow figures leave out.
  • Share dilution. Diluted shares rose 15.3% in a year.

Latest results: FY2026 Q2

Filed August 5, 2026
Earnings per share
-$0.80 against an average estimate of -$0.75: missed by 7.4%
Revenue
$176m, up 37.9% on a year earlier
Share reaction
-9.8% in the first session after the results on August 5, 2026, against -0.4% for the S&P 500
Guidance given
net product sales guidance $680m to $700m (2026)
Next report
November 3, 2026; average EPS estimate -$0.41

Mirum Pharmaceuticals' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day+1.1%
  • 1 week+1.3%
  • 1 month+4.5%
  • This year+8.5%
  • 1 year+22.4%
  • 5 years+433.9%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$618M
Operating margin
-134.9%
Net margin
-139.2%
EPS (TTM, diluted)
$-15.33

Growth

Revenue growth
+44.0%
Change in growth rate
−6.2 pts
Share count change
+15.3%

Cash

Free cash flow (TTM)
-$229M
FCF margin
-37.0%
Stock pay % of revenue
16.8%

Earnings

Last results
August 5, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Announcement
  2. Announcement
  3. Announcement
  4. Leadership
  5. Insider trade
  6. Insider trade
  7. Insider trade
  8. Results
  9. Guidance
  10. Insider trade

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Mirum Pharmaceuticals, Inc. valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: free cash flow after stock pay is not positive.

The inputs used by the models below have passed source checks. Individual model values are available below and in the interactive valuator. Their differences are shown explicitly; the platform combined value and recommendation remain withheld.

Valuation models

We value Mirum Pharmaceuticals, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 9.1%: the 10-year Treasury yield (4.9%) plus a beta of 0.93 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. ~$15 ~$8.2–$23 Left out: out of range vs price (0.17x)
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: This model is withheld pending its input or assumption review.
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: This model is withheld pending its input or assumption review.
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: This model is withheld pending its input or assumption review.
Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. ~$12 ~$26–$90 Left out: out of range vs price (0.13x)
Combined value Individual source-checked model scenarios are available. The platform combined value and recommendation remain withheld. — Combined value withheld. Review the individual models and their assumptions.

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Mirum Pharmaceuticals, Inc. with Biotechnology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 202020212022202320242025Now
Share price$17.46$15.95$19.50$29.52$41.35$78.99$85.74
Market value$441m$484m$663m$1.2bn$2.0bn$4.0bn$4.8bn
+ Net debt (− = net cash)−$142m−$31m−$28m$20m$86m$13m$419m
Enterprise value$299m$452m$635m$1.2bn$2.1bn$4.0bn$5.2bn
Multiples
Price / sales —25.3x8.6x6.5x5.8x7.6x7.8x
Price / earnings ———————
Price / free cash flow ————n/m72.3x—
EV / EBITDA —————n/m—

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

10 /100

Weak moat

How hard Mirum Pharmaceuticals's competitive advantage looks for rivals to wear away, judged from 8 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 0 / 20

    Net income has been a median -37.5% of total assets over 8 years.

  • Durability 10 / 20

    Operating margin has been a median -118.6%; its worst year was -1306.2%.

  • Cash conversion 2 / 20

    Free cash flow was positive in 1 of 6 years, at a median -60.3% of revenue.

  • Discipline 0 / 20

    The diluted share count rose 101.0% over five years; stock-based pay has been a median 21.7% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (15 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 3, 2026, after the close. Analysts expect revenue of $178m and EPS of −$0.41 (range −$0.53 to −$0.30) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$15.23 −3140% $698m +34%
Next −$0.70 +95% $820m +17%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is +7.0% on 90 days ago. In the last 30 days, 0 analysts raised Mirum Pharmaceuticals, Inc.'s forecast and 0 cut it.

Consensus EPS forecast Mirum Pharmaceuticals, Inc., last 90 days
−$20.00 −$15.00 −$10.00 −$5.00 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$14.24 Current fiscal year, 60 days ago: −$15.14 Current fiscal year, 30 days ago: −$15.14 Current fiscal year, 7 days ago: −$15.14 Current fiscal year, Now: −$15.23 −$15.23 Next fiscal year, 90 days ago: −$0.19 Next fiscal year, 60 days ago: −$0.35 Next fiscal year, 30 days ago: −$0.35 Next fiscal year, 7 days ago: −$0.35 Next fiscal year, Now: −$0.70 −$0.70

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$14.24−$0.19
60 days ago −$15.14−$0.35
30 days ago −$15.14−$0.35
7 days ago −$15.14−$0.35
Now −$15.23−$0.70

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$0.75 −$0.80 −7.4%
Mar 2026 −$0.35 −$1.08 −205.6%
Dec 2025 $0.06 −$0.12 −308.7%
Sept 2025 −$0.16 $0.05 +131.5%

Adjusted EPS as companies report it, against the average analyst estimate.

Management guidance

Earnings release, August 5, 2026
  • Net product sales guidance 2026 $680m to $700m Raised
    “2026 net product sales guidance increased to $680 million to $700 million” source

Figures and quotations are management's, copied from the company's own press release (SEC 8-K exhibit) and checked word for word against it. Forward-looking statements are the company's expectations, not ours and not advice; guidance can change or be missed.

Analyst recommendations

14 analysts, Oct 2026
Buy14100%
Hold00%
Sell00%

Monthly trend

  1. Oct 202641014
  2. Sep 202641014
  3. Aug 202641014
  4. Jul 202641014

Counts of recommendations published by analysts covering Mirum Pharmaceuticals, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
13.2%
of tradable shares
Days to cover
7.16
at average volume
Short interest, 1 month
+6%
to October 15, 2026
Held by institutions
—
of shares
Held by insiders
1.3%
of shares
Employees
433
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

What moved the share price

Last 12 months +18.0%

$72.65 on October 31, 2025 to $85.74

ThenNowEffect
Revenue (last 12 months) $429m $618m +44.0%
P/S multiple 8.2x 7.8x −5.5%
Share count 49m 56m −13.3%

Biggest factor: revenue. Loss-making at one end, so the split uses price/sales.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
MIRM−9%+22%+51%+40%+91%+9%
Industry peers (median)−36%−57%−18%−29%−5%−27%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
MIRM58%50%58%42%58%55%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
MIRM−41%−40%−18%−22%−28%−38%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since July 18, 2019: 64% from December 27, 2019 to March 18, 2020. Getting back needed a 176% gain, reached on August 10, 2020, 145 days after the low.

Price behaviour

52-week range
$64.10 – $128.57
From 52-week high
−33.3%
vs 50-day average
−4.4%
vs 200-day average
−13.0%
Volatility (1 year)
47%
Beta vs S&P 500
1.09

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
6 up, 6 down
typical move ±6.4%
After a week
8 up, 4 down
typical move ±8.3%
After a month
7 up, 5 down
typical move ±12.4%
Results releasedNext dayS&P 500 next day5 days21 days
August 5, 2026 −9.8% −0.4% −5.1% −3.5%
May 6, 2026 −2.7% +1.1% +3.2% −11.7%
February 25, 2026 −14.2% +0.3% −13.4% −17.3%
January 12, 2026 +4.5% 0.0% +6.1% +15.4%
November 4, 2025 −1.1% −0.8% +0.7% +1.0%
August 6, 2025 +15.4% +0.7% +25.7% +46.7%
May 7, 2025 +10.3% +1.1% +8.3% +13.1%
February 26, 2025 −5.9% −1.5% −10.6% −7.7%
January 13, 2025 +4.8% +0.3% +16.1% +22.7%
November 12, 2024 +5.6% −0.3% +1.2% +1.6%
August 7, 2024 +1.8% +1.6% +6.0% +5.0%
May 8, 2024 −0.3% +0.6% −3.6% −3.2%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Mirum Pharmaceuticals, Inc. in five measures

Fundamentals grade C
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Mirum Pharmaceuticals, Inc.
$0 $200M $400M $600M $800M FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue (TTM), FY23 Q3: $144.7M Revenue (TTM), FY23 Q4: $186.4M Revenue (TTM), FY24 Q1: $224M Revenue (TTM), FY24 Q2: $264.4M Revenue (TTM), FY24 Q3: $307M Revenue (TTM), FY24 Q4: $336.9M Revenue (TTM), FY25 Q1: $379.3M Revenue (TTM), FY25 Q2: $429.2M Revenue (TTM), FY25 Q3: $471.8M Revenue (TTM), FY25 Q4: $521.3M Revenue (TTM), FY26 Q1: $569.6M Revenue (TTM), FY26 Q2: $618.1M $618.1M

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue (TTM)
FY23 Q3 $144.7M
FY23 Q4 $186.4M
FY24 Q1 $224M
FY24 Q2 $264.4M
FY24 Q3 $307M
FY24 Q4 $336.9M
FY25 Q1 $379.3M
FY25 Q2 $429.2M
FY25 Q3 $471.8M
FY25 Q4 $521.3M
FY26 Q1 $569.6M
FY26 Q2 $618.1M
Revenue growth, TTM YoY Mirum Pharmaceuticals, Inc.
0% 50% 100% 150% 200% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue growth, TTM YoY, FY23 Q3: 176.8% Revenue growth, TTM YoY, FY23 Q4: 141.8% Revenue growth, TTM YoY, FY24 Q1: 133.9% Revenue growth, TTM YoY, FY24 Q2: 128.3% Revenue growth, TTM YoY, FY24 Q3: 112.1% Revenue growth, TTM YoY, FY24 Q4: 80.8% Revenue growth, TTM YoY, FY25 Q1: 69.3% Revenue growth, TTM YoY, FY25 Q2: 62.3% Revenue growth, TTM YoY, FY25 Q3: 53.7% Revenue growth, TTM YoY, FY25 Q4: 54.7% Revenue growth, TTM YoY, FY26 Q1: 50.2% Revenue growth, TTM YoY, FY26 Q2: 44.0% 44.0%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q3 176.8%
FY23 Q4 141.8%
FY24 Q1 133.9%
FY24 Q2 128.3%
FY24 Q3 112.1%
FY24 Q4 80.8%
FY25 Q1 69.3%
FY25 Q2 62.3%
FY25 Q3 53.7%
FY25 Q4 54.7%
FY26 Q1 50.2%
FY26 Q2 44.0%
Operating margin (TTM) Mirum Pharmaceuticals, Inc.
-150% -100% -50% 0% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Operating margin (TTM), FY23 Q3: -76.5% Operating margin (TTM), FY23 Q4: -58.6% Operating margin (TTM), FY24 Q1: -48.4% Operating margin (TTM), FY24 Q2: -41.0% Operating margin (TTM), FY24 Q3: -31.3% Operating margin (TTM), FY24 Q4: -26.0% Operating margin (TTM), FY25 Q1: -20.1% Operating margin (TTM), FY25 Q2: -13.3% Operating margin (TTM), FY25 Q3: -8.9% Operating margin (TTM), FY25 Q4: -4.2% Operating margin (TTM), FY26 Q1: -139.8% Operating margin (TTM), FY26 Q2: -134.9% -134.9%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q3 -76.5%
FY23 Q4 -58.6%
FY24 Q1 -48.4%
FY24 Q2 -41.0%
FY24 Q3 -31.3%
FY24 Q4 -26.0%
FY25 Q1 -20.1%
FY25 Q2 -13.3%
FY25 Q3 -8.9%
FY25 Q4 -4.2%
FY26 Q1 -139.8%
FY26 Q2 -134.9%
FCF margin (TTM) Mirum Pharmaceuticals, Inc.
-80% -60% -40% -20% 0% 20% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 FCF margin (TTM), FY23 Q3: -61.5% FCF margin (TTM), FY23 Q4: -38.1% FCF margin (TTM), FY24 Q1: -16.5% FCF margin (TTM), FY24 Q2: -9.2% FCF margin (TTM), FY24 Q3: -0.7% FCF margin (TTM), FY24 Q4: 2.8% FCF margin (TTM), FY25 Q1: -2.1% FCF margin (TTM), FY25 Q2: 2.0% FCF margin (TTM), FY25 Q3: 9.4% FCF margin (TTM), FY25 Q4: 10.5% FCF margin (TTM), FY26 Q1: -30.3% FCF margin (TTM), FY26 Q2: -37.0% -37.0%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q3 -61.5%
FY23 Q4 -38.1%
FY24 Q1 -16.5%
FY24 Q2 -9.2%
FY24 Q3 -0.7%
FY24 Q4 2.8%
FY25 Q1 -2.1%
FY25 Q2 2.0%
FY25 Q3 9.4%
FY25 Q4 10.5%
FY26 Q1 -30.3%
FY26 Q2 -37.0%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Jun 2026
Income
Revenue 0 19 77 186 337 521 618
EBITDA −104 −173 −128 −98 −64 2 −808
Operating income −104 −173 −131 −109 −88 −22 −834
Net income −103 −84 −136 −163 −88 −23 −860
Diluted EPS −$4.09 −$2.77 −$4.02 −$4.00 −$1.85 −$0.47 −$15.33
Growth (year on year)
Revenue — — +302.7% +141.8% +80.8% +54.7% +44.0%
Margins
EBITDA margin — −903.0% −166.1% −52.8% −19.0% 0.4% −130.7%
Operating margin — −906.1% −170.3% −58.6% −26.0% −4.2% −134.9%
Net margin — −438.9% −176.0% −87.7% −26.1% −4.5% −139.2%
Free-cash-flow margin — −693.8% −156.3% −38.1% 2.8% 10.5% −37.0%
Cash flow
Cash from operations −89 −133 −120 −71 10 56 −227
Capital spending 0 0 0 0 1 1 1
Free cash flow −89 −133 −120 −71 9 55 −229
Stock-based pay 13 23 27 35 48 71 104
Free cash flow after stock pay −102 −156 −147 −106 −39 −17 −333
Balance sheet
Cash 142 31 28 286 223 297 331
Total debt 0 0 0 306 308 310 750
Net debt (negative = net cash) −142 −31 −28 20 86 13 419
Diluted shares 25m 30m 34m 41m 48m 50m 56m

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

1 of 5 checks passed · June 30, 2026
What it owns · $1.0bn
Short-term assets $636mLonger-term assets $409m
What it owes, and who funded it · $1.1bn
Short-term liabilities $223mLonger-term liabilities $833mShareholders' equity $-10m
  • Short-term assets cover short-term liabilities $636m of assets due within a year against $223m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $636m short-term assets against $833m of longer-dated liabilities.
  • More cash than debt $331m of cash against $750m of debt.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt −$227m of operating cash flow against $750m of debt.
  • Operating profit covers interest at least five times over Operating income of −$834m against $13m of interest.

From Mirum Pharmaceuticals, Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

Diluted share count
+15.3%
year over year
R&D spending
45.7%
of revenue
Sales & admin spending
50.8%
of revenue
Days sales outstanding
86 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in biotechnology
Last 12 months unless stated MIRM TARS ARWR HCM NRIX RARE Median
Revenue, last 12 months $618m $606m $669m $549m $702m $717m $56m
Revenue growth, last 12 months 44.0% 105.2% 16.8% −13.0% 738.8% 17.5% 12.6%
Revenue growth, 3-year average 74.8% 264.7% 37.7% — 117.1% 21.2% 13.7%
Revenue growth, latest quarter 37.9% 69.4% 171.0% — >999% 28.1% 10.2%
Gross margin — — — 38.7% — 97.2% 82.9%
Operating margin −134.9% −8.0% −33.8% −7.1% 41.3% −73.6% −189.4%
Operating margin, 3-year average −63.1% −76.2% −945.9% −40.5% −207.1% −90.2% −363.5%
Net margin −139.2% −7.7% −47.8% 83.3% 42.0% −81.7% −169.8%
Cash from operations / revenue −36.8% 12.2% −8.8% −11.8% 54.0% −67.6% −168.0%
Free-cash-flow margin −37.0% 9.2% −11.2% −14.4% 52.7% −68.2% −162.4%
Free-cash-flow margin, 3-year average −14.7% −56.4% −908.4% −27.4% −141.7% −79.3% −310.0%
Stock pay / revenue 16.8% 8.5% 10.5% 2.6% 5.8% 15.1% 20.0%
Change in share count 15.3% 8.0% 7.8% 0.0% 31.0% 4.2% 8.2%

Median of all 184 companies we cover in biotechnology. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

184 biotechnology companies
Measure Company Peer median Rank
Revenue growth Growth 44.0% 12.6% 57 of 172
Change in growth rate Growth -6.2pp -0.1pp 108 of 172
Operating margin Profitability -134.9% -189.4% 82 of 175
Net margin Profitability -139.2% -157.3% 85 of 180
Free-cash-flow margin Cash generation -37.0% -145.4% 58 of 176
Stock pay as % of revenue Cash generation 16.8% 19.2% 83 of 179
Long-term debt as % of assets Balance sheet 71.8% 20.6% 74 of 78
Change in share count Balance sheet 15.3% 7.9% 105 of 156
Days sales outstanding Balance sheet 86 days 75 days 57 of 100

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue Share YoY
Products $521M 100.0% ▲ 55.0%
Livmarli $360M 69.1% ▲ 68.8%
Bile Acid Medicines $161M 30.9% ▲ 31.0%
License and Other Revenue $0 0.0% ▼ 100.0%

From Mirum Pharmaceuticals, Inc.'s 10-K filed February 25, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Who owns it

Funds buying and selling
Reported value
$8.4B
Institutions reporting
324
Shares held vs prior quarter
▲ 4.7%
Positions opened / closed
59 / 42

Top buyers and sellers, Q2 2026: 185 institutions bought and 141 sold ; the biggest buyer was FMR LLC (+1.7M shares) and the biggest seller Citadel Advisors LLC (−1.1M). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Frazier Life Sciences Management, L.P. $899M 7.7M 10.7% 0.0%
Jupiter Topco LLC $692M 5.9M 8.3% —
Blackrock, Inc. $514M 4.4M 6.1% ▲ 14.1%
FMR LLC $430M 3.7M 5.1% ▲ 86.7%
Price T Rowe Associates Inc $311M 2.7M 3.7% ▲ 54.6%
Vanguard Portfolio Management LLC $278M 2.4M 3.3% ▲ 66.0%
Vanguard Capital Management LLC $264M 2.3M 3.2% ▼ 6.7%
State Street Corp $254M 2.2M 3.0% ▲ 11.6%
William Blair Investment Management, LLC $164M 1.4M 2.0% ▲ 318.5%
Geode Capital Management, LLC $163M 1.4M 2.0% ▲ 10.6%
Invesco Ltd. $160M 1.4M 1.9% ▲ 378.2%
Wellington Management Group LLP $153M 1.3M 1.8% ▼ 1.9%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Mirum Pharmaceuticals, Inc.'s complete shareholder register. Values are as reported by the filers ; 5 inconsistently scaled filing rows were excluded.

Insider trading activity

Full insider history and chart
Insider purchases History → $9M 1 trade by 1 insider, last 12 months Insider sales History → $42.2M 59 trades by 7 insiders · 61% under pre-set plans
Net ▼ $33.2M net selling
Insider Date Trade Shares Price Value
Bjerkholt Eric CHIEF FINANCIAL OFFICER September 14, 2026 Sell 9,943 $98.37 $978,093
Howe Jolanda SVP, GLOBAL CONTROLLER September 2, 2026 Sell pre-set plan 658 $100.00 $65,800
Peetz Christopher CHIEF EXECUTIVE OFFICER September 1, 2026 Sell pre-set plan 21,688 $98.91 $2.1M
Peetz Christopher CHIEF EXECUTIVE OFFICER September 1, 2026 Sell pre-set plan 8,312 $98.08 $815,241
Howe Jolanda SVP, GLOBAL CONTROLLER August 18, 2026 Sell 40,000 $100.00 $4M
Bjerkholt Eric CHIEF FINANCIAL OFFICER August 11, 2026 Sell pre-set plan 6,001 $99.90 $599,500
Peetz Christopher CHIEF EXECUTIVE OFFICER August 10, 2026 Sell pre-set plan 2,300 $100.14 $230,322
Peetz Christopher CHIEF EXECUTIVE OFFICER August 10, 2026 Sell pre-set plan 11,683 $98.51 $1.2M
Peetz Christopher CHIEF EXECUTIVE OFFICER August 10, 2026 Sell pre-set plan 6,017 $99.25 $597,187
Howe Jolanda SVP, GLOBAL CONTROLLER August 3, 2026 Sell pre-set plan 1,840 $105.29 $193,734
Bjerkholt Eric CHIEF FINANCIAL OFFICER July 6, 2026 Sell pre-set plan 3,124 $121.67 $380,097
Bjerkholt Eric CHIEF FINANCIAL OFFICER July 6, 2026 Sell pre-set plan 1,048 $122.43 $128,307

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around October 14, 2026 estimated from the company's past filing pattern, not announced

  • August 5, 2026
  • May 6, 2026
  • February 25, 2026
  • January 12, 2026
  • November 4, 2025
  • August 6, 2025

Recent SEC filings

Data status

When each part of this page on Mirum Pharmaceuticals, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Mirum Pharmaceuticals, Inc. in brief

What does Mirum Pharmaceuticals, Inc. do?
Mirum Pharmaceuticals, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
What is Mirum Pharmaceuticals, Inc.'s stock ticker?
Mirum Pharmaceuticals, Inc. trades under the ticker MIRM on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Mirum Pharmaceuticals, Inc.'s revenue, and how fast is it growing?
Over its most recent trailing twelve months, Mirum Pharmaceuticals, Inc. reported revenue of $618M, 44.0% higher than a year earlier, according to its SEC filings.
What is Mirum Pharmaceuticals, Inc.'s free cash flow?
Mirum Pharmaceuticals, Inc.'s free-cash-flow margin is -37.0% of revenue over the trailing twelve months, ranking 58 of the 176 biotechnology companies we cover.
Who are Mirum Pharmaceuticals, Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Frazier Life Sciences Management, L.P., Jupiter Topco LLC and Blackrock, Inc. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Mirum Pharmaceuticals, Inc.'s market cap?
On November 2, 2026, Mirum Pharmaceuticals, Inc.'s market capitalisation was about $4.8B and net debt of $419M. Market figures come from third-party market data and may be delayed.
Who are Mirum Pharmaceuticals, Inc.'s competitors?
In our Biotechnology peer group, the companies closest to Mirum Pharmaceuticals, Inc. are Tarsus Pharmaceuticals, Inc., Arrowhead Pharmaceuticals, Inc., Hutchmed (china) Ltd, Nurix Therapeutics, Inc. and Ultragenyx Pharmaceutical Inc. The side-by-side comparison below sets their revenue, margins and growth against Mirum Pharmaceuticals, Inc.'s.
Are insiders buying or selling Mirum Pharmaceuticals, Inc. stock?
Over the last 12 months, Mirum Pharmaceuticals, Inc.'s directors and officers reported 1 open-market purchases and 59 sales on Form 4. The insider trading page charts every trade.
When is Mirum Pharmaceuticals, Inc.'s next earnings date?
Around November 3, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Mirum Pharmaceuticals, Inc. announces its own schedule.